Get started

PFE

Bullish Charts - Oversold & Undervalued Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, such as cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; oncology, such as biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, and tick-borne encephalitis under the Prevnar 13/Prevenar 13 (pediatric/adult), FSME-IMMUN, Nimenrix, and Trumenba brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, Genotropin, and Refacto AF/Xyntha brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company and Astellas Pharma US, Inc.; licensing agreement with Akcea Therapeutics, Inc; strategic alliance with Verily Life Sciences LLC; collaboration agreement with Merck KGaA; clinical trial collaboration and supply agreement with IDEAYA Biosciences, Inc.; material transfer and collaboration agreement with BioNTech SE to co-develop COVID-19 vaccine; clinical supply collaboration Jiangsu Alphamab Biopharmaceuticals Co., Ltd; and collaboration with Valneva SE to develop and commercialize Valneva's Lyme disease vaccine candidate VLA15. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer is one of the most unappreciated stocks in its industry and the low price shows. Recently, institutions have taken notice and started upgrading the stock with price targets north of $40.00 a share. Pfizer is also working on a COVID-19 vaccine and could be months ahead of other companies. On the daily chart, the stock is sitting is sitting and bouncing off support around $33.00. It's ready for a move up any day. Long!
NYSE:PFELong
by HotCharts
Pfizer: PFE. Hardly any downside. Perfect Entry.The bad news with Pfizer's clinical trial is great news for traders and investors. Why? Because the 'bottom' has been gauged by this piece of over the weekend news. The bad news does not materially affect existing revenue stream and earnings. The lack of movement intraday suggests that institutions have completely priced in the negative effect of the news before market open. Anyone who wanted and NEEDED to sell has mostly sold, and there was no lack of buyers to take those orders at the $35.50. Perfect opportunity for a long trade, short term or long. Anything above 34.50 is a BUY. Interval Targets are the Fibonacci levels on the chart. Final target: $45
NYSE:PFELong
by yujingr
Pfizer Shizer; Do the Bears Have this One? 🏥 | PFIZER ($PFE)🧑‍⚕️ Pfizer recently announced that a clinical trial of its drug Ibrance hasn't worked out as a long-term treatment for breast cancer. This news is unfortunate on a few levels, but specifically, in terms of price, the impact isn't great. Upon releasing the news PFE dumped as analyst began to revise earnings expectations downward. This sell-off caused a reversal of the shorter term post-COVID downtrend and caused what appears to be a return to the pre-COVID downtrend. While we do think a short setup makes sense here given the facts, there is plenty of reason to be bullish from a longer-term point of view given Pfizer's projection that it could have a COVID vaccine by fall and given their funding of other COVID companies working on treatments. Resources: www.jpost.com + www.marketwatch.com + www.barrons.com ✨ Drop a comment asking for an update, we do NEW setups every day! ✨ Like, Comment & Follow to help the community grow 🎉🎉 --- 1. Fractal Trend is showing a fresh downtrend (Maroon colored bars) on the 1-hour timeframe. 2. With this strategy, we are looking for short setups in an downtrend and as such want to enter short on retests of bearish order blocks plotted by Orderblock Mapping (Maroon colored lines) and/or bearish S/R levels plotted by Directional Bias (Maroon colored lines). 3. The play here is simple, we are looking for a reaction at the R1 S/R flip and then are targeting the S1 orderblock at the current low. Then, by placing a stop just above the S/R flip, we have ourselves a solid 4.09 risk/reward ratio. 4. Other levels to the upside to watch here are R2 and R3 bearish orderblocks which should see a reaction if and when we move to the upside. 5. Below, the S2 and S3 bullish orderblocks should provide support if we move to the downside. Keep in mind we are only looking to short weakness in the near term here, as time goes on PFE should find support and potential COVID cures could easily send this stock back up. Until then, good luck bears!
NYSE:PFE
by AlphaBotSystem
1
PFE - A Multi Time-Frame Analysis.Hello investors! Today I’m going to talk about PFIZER, the only stock I own that is giving me some loss . I think it’s still worth to long it, and here’s my reasons. We see a triangle in the hourly chart, and an upwards breakout would be more desirable than a downwards because there’re less resistances than supports. Also, take a look at the daily chart: There’s a flag here! And if the price breakout from it, PFE will trigger a pivot (green lines). I know, the volume is low, and yes, it bugs me, but it’s a trade with a great risk/reward relationship! Now, you wouldn’t still be here if you didn’t find this analysis interesting, right? In this case, please, support this idea and follow me to keep in touch! Now, let’s take a look at the weekly chart: We are close to a trendline, a natural resistance for the price, but with all the good signs, I think it’s still worth. I’m long here since May 15, along with TSN, HCA, CMSCA, ITUB and TWTR, I posted about them in my social media, check it there! Also, I hold XP and LB, and I posted their analyses here, the link to them are below. Remember to follow me, I’m a trader who uses the classic technical analysis (barely any indicator, just the candles and the volume). Like this idea if it helped. Thank you very much. * LIKE this idea and FOLLOW me, because: - Here, you will see clean charts; - Trades with clear risk management; - The best of Dow Theory, Price Action and Candlestick psychology; - Chart patterns with statistics. * * My name is Nathan, I'm a trader and portfolio manager and I'm here to LEARN. Leave your COMMENT and FOLLOW me to keep in touch. *
NYSE:PFELong
by Nathan_The_Finance_Hydra
4
PFE is Proof Today is a Bad Day for the Stock MarketFirst off, please don't take anything I say seriously or as financial advice. As always, this is on opinion based basis. That being said, PFE recently came out with news that they are working towards a Covid19 vaccine by October. They were already on a mostly bullish run until recently. That being said, the chart patterns were already indicating positive. The fact that they didn't rally and sentiment analysis didn't push it the same way Moderna did when it came with similar news stories, leads me to believe that today was obviously a bad day in general for the stock market.
NYSE:PFEShort
by gamer456148
1
Pfizer -PFE - Technical and Fundamental AnalysisTechnical Analysis: Wait that the upper resistance line will be broken before buying. The prices are in a sideways trend, theoretically they should resume their previous trend (uptrend) breaking the top resistance dotted line. Fundamental Analysis: Pharmaceutical giant Pfizer (NYSE:PFE), which is working alongside German drugmaker BioNTech (NASDAQ:BNTX) to develop a coronavirus vaccine, says it should have initial data from its stage one clinical trial in mid-to-late June.
NYSE:PFELong
by Mauriello
PFE: $40 Threshold Crossing Potential + >$45 Price & lrg SpreadFirst off, please don't take anything I say seriously or as financial advice. As always, this is on opinion based basis. That being said, the market today and tomorrow doesn't look so bright given the DOW drop and the expected negative Federal Reserve announcement coming tomorrow. That being said, it is best likely to trade late Thursday or early Friday in my opinion. I expect realistically that Pfizer will soon pass the $40 threshold, and it it does, it may even rally to the $45+ price point as a short.
NYSE:PFEShort
by gamer456148